Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.46), $0.76 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $331.8 million versus the consensus estimate of $285.83 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.